Paltusotine is a selective somatostatin receptor agonist indicated for the treatment of acromegaly, a condition characterized by excessive growth hormone production. By targeting the somatostatin receptor… Read more
Paltusotine is a selective somatostatin receptor agonist indicated for the treatment of acromegaly, a condition characterized by excessive growth hormone production. By targeting the somatostatin receptor subtype 2, this medication effectively modulates growth hormone and insulin-like growth factor 1 levels. To support the rigorous analytical testing required during pharmaceutical development and regulatory compliance, laboratories utilize a specialized range of related compounds. This category includes Paltusotine impurities, metabolites, and stable isotope-labelled standards, which are essential for accurate impurity profiling and method validation. These high-quality reference standards are vital for establishing robust quality control processes, allowing researchers to quantify drug content and identify degradation products with precision. By providing the necessary chemical markers for identification and assay development, these compounds assist analytical chemists in maintaining strict adherence to safety and purity protocols throughout the lifecycle of the drug.